Gastric Cancer, Osteoporosis, Sarcopenia
Conditions
Brief summary
Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after gastrectomy. In total gastrectomy and distal gastrectomy groups, at least 5 years should have elapsed since gastrectomy.
Detailed description
The patients after gastrectomy loss appetite and decrease the weight. Total gastrectomy especially cause severe sarcopenia and metabolic change. Osteoporosis after gastrectomy, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after gastrectomy. The primary tools for assessing volumetric density and bone structure are quantitative computed tomography (QCT) and more recently, high-resolution peripheral quantitative computed tomography (HR-pQCT). However the validation of osteoporosis with HR-pQCT in the long course after gastrectomy remain elusive. The aim of the present study was to evaluate osteoporosis by using HR-pQCT in the long course after gastrectomy. In total gastrectomy and distal gastrectomy groups, at least 5 years should have elapsed since gastrectomy.
Interventions
PROCEDUREgastrectomy
Distal gastrectomy, Total gastrectomy
Sponsors
Kobayashi Shinichiro
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
60 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* At least 5 years have elapsed since DG or TG due to gastric cancer * Provide signed informed consent
Exclusion criteria
* pregnancy * Current use of the following osteoporosis agents; Teriparatide, Denosumab, and bisphosphonate * Hyperthyroidism * Hyperparathyroidism * Present malignancy (except in situ carcinoma) * Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy * Other diseases which affect bone metabolism * Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures * Received \> 3 months (or equivalent) of osteoporosis treatment * Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparing bone microstructure in control, DG, and TG groups | day1 | volumetric bone mineral density |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparing bone microstructure with serum biomarkers of osteoporosis | day1 | Correlation between bone mineral density in HR-pQCT and biomarkers (25-hydroxyvitaminD, calcium, iPTH, P1NP, ICTP, TRACP5b) |
| Comparing bone microstructure with dual-energy X-ray absorptiometry | day1 | Correlation of bone mineral density between HR-pQCT and DXA |
| Comparing bone microstructure with sarcopenia | day1 | Correlation between bone mineral density in HR-pQCT and cross-sectional area of the abdominal psoas major muscle |
| Comparing bone microstructure with quality of life (BDHQ) | day1 | Patients will be asked to complete a short debriefing questionnaire covering questions ( BDHQ) |
| Comparing bone microstructure with quality of life (FRAX) | day1 | Patients will be asked to complete a short debriefing questionnaire covering questions (FRAX) |
| Comparing bone microstructure with quality of life (QOL-C30) | day1 | Patients will be asked to complete a short debriefing questionnaire covering questions (QOL-C30) |
Countries
Japan
Contacts
Primary ContactShinichiro Kobayashi, MD
Outcome results
None listed